Wilson Disease Association’s Annual Conference

Vivet Therapeutics is delighted to sponsor and present at @Wilson Disease Association’s Annual Conference for patients and caregivers. Be sure to tune in to the presentation of CMO Bernard Benichou, MD, Ph.D, and Patient Advocate Lori McKenna Gorski!

Vivet presenting at 6th annual Gene Therapy for Rare Disorders Europe in London

Vivet will be attending and presenting during 6th annual Gene Therapy for Rare Disorders Europe in London. “Gain European Regulatory Clarity to Progress Efficient & Robust Gene Therapies for Rare Disease” is this year’s theme. Vivet Therapeutic’s Chief Development Officer, Anne Douar, will participate to 2 sessions: ? Anne will talk about “Developing a Strategy […]

Vivet presenting during 3rd annual Gene Therapy Immunogenicity Conference in Boston – Oct. 18-20 2022

Vivet will be attending and presenting during 3rd annual Gene Therapy Immunogenicity Conference in Boston. Overcoming Translational Hurdles, Improving Immunology Assays & Optimizing Clinical Strategies for Mitigating Adverse Immune Responses are gene therapy’s biggest challenges today. Vivet Therapeutic’s Co-Founder & Chief Executive Officer, Jean-Philippe Combal, will address some of these challenges as part of the panel […]

Vivet presenting during next ESGCT congress in Edinburgh – Oct. 11-14, 2022

Vivet will be attending and presenting some new and exciting results from its different programs and platforms this week at the upcoming ESGCT congress in Edinburgh. 2️⃣ presentations planned: ?Key data about seroprevalence of anti-adeno-associated virus 3B neutralizing antibodies in an international cohort of 200 healthy donors. These results will be presented by Blanche Tamarit (P515; […]

Vivet presenting during the 1st Annual Optimizing AAV Safety Summit in Boston – Sept. 6-8, 2022

Vivet will be attending and presenting during the 1st Annual Optimizing AAV Safety Summit in Boston. With hundreds of clinical trials using AAV currently underway, it has never before been so important to create and implement an effective AAV safety strategy. Improving prediction of AAV toxicity, accurately monitoring potential safety signals, extracting safety data from non-clinical […]